UniSuper Management Pty Ltd Acquires 1,754 Shares of Agilent Technologies, Inc. $A

UniSuper Management Pty Ltd grew its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 7.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,655 shares of the medical research company’s stock after acquiring an additional 1,754 shares during the period. UniSuper Management Pty Ltd’s holdings in Agilent Technologies were worth $3,118,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of A. Whipplewood Advisors LLC grew its position in shares of Agilent Technologies by 286.2% during the 1st quarter. Whipplewood Advisors LLC now owns 251 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 186 shares during the period. Sunbelt Securities Inc. grew its position in shares of Agilent Technologies by 640.0% during the 4th quarter. Sunbelt Securities Inc. now owns 222 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 192 shares during the period. Stone House Investment Management LLC purchased a new position in Agilent Technologies during the first quarter valued at approximately $30,000. Opal Wealth Advisors LLC purchased a new position in Agilent Technologies during the first quarter valued at approximately $31,000. Finally, Wood Tarver Financial Group LLC purchased a new position in Agilent Technologies during the fourth quarter valued at approximately $34,000. Institutional investors own 87.41% of the company’s stock.

Insider Buying and Selling

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of the business’s stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total value of $177,099.52. Following the sale, the chief executive officer owned 37,448 shares in the company, valued at $4,397,893.12. The trade was a 3.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.26% of the stock is currently owned by insiders.

Analyst Ratings Changes

A has been the topic of several analyst reports. TD Cowen lifted their price target on shares of Agilent Technologies to $150.00 and gave the company a “buy” rating in a report on Thursday, May 29th. UBS Group lowered their price target on shares of Agilent Technologies from $150.00 to $130.00 and set a “neutral” rating on the stock in a report on Thursday, May 29th. Leerink Partners lifted their price target on shares of Agilent Technologies to $135.00 and gave the company a “buy” rating in a report on Friday, May 30th. Wall Street Zen downgraded shares of Agilent Technologies from a “buy” rating to a “hold” rating in a report on Friday, September 5th. Finally, Evercore ISI lowered their price target on shares of Agilent Technologies from $130.00 to $128.00 and set an “in-line” rating on the stock in a report on Thursday, August 28th. Six research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $139.25.

Agilent Technologies Stock Down 1.4%

Shares of A stock opened at $126.37 on Wednesday. The stock has a market cap of $35.83 billion, a P/E ratio of 29.66, a PEG ratio of 3.99 and a beta of 1.24. Agilent Technologies, Inc. has a 52 week low of $96.43 and a 52 week high of $153.84. The company has a quick ratio of 1.71, a current ratio of 2.25 and a debt-to-equity ratio of 0.53. The company’s fifty day simple moving average is $119.54 and its two-hundred day simple moving average is $116.07.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, hitting the consensus estimate of $1.37. The business had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The business’s quarterly revenue was up 10.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.32 EPS. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Analysts predict that Agilent Technologies, Inc. will post 5.58 EPS for the current fiscal year.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.